Shares of CRISPR Therapeutics AG (CRSP) have gained 11.4% over the past four weeks to close the last trading session at $50.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $81.96 indicates a potential upside of 62.8%.The mean estimate comprises 24 short-term price targets with a standard deviation of $34.57. While the lowest estimate of $30 indicates a 40.4% decline from the ...

Core Insights - CRISPR Therapeutics reported a narrower loss of $1.01 per share for Q3 2024, compared to the Zacks Consensus Estimate of a loss of $1.33 and a loss of $1.41 per share in the same period last year [1] - Total revenues were $0.6 million, primarily from grant revenues, significantly missing the Zacks Consensus Estimate of $6.4 million [1] - The company had cash and equivalents of $1.9 billion as of September 30, 2024, down from $2.0 billion as of June 30, 2024 [3] Financial Performance - Research and development expenses decreased by 9% year over year to $82.2 million due to reduced external research and manufacturing costs [2] - General and administrative expenses fell by 5% year over year to $17.4 million [2] - Collaboration expenses were $11.2 million, down 52% year over year, mainly due to delays in reaching the deferral limit on costs related to the Casgevy program [2] Pipeline Developments - CRISPR and Vertex Pharmaceuticals' gene therapy, Casgevy, was approved for sickle cell disease and transfusion-dependent beta thalassemia in late 2023/early 2024 [5] - More than 45 authorized treatment centers have been activated globally since mid-October, with Vertex reporting $2 million in product revenues from Casgevy sales [6] - CRISPR is developing next-generation CAR-T therapies, CTX112 and CTX131, currently in separate phase I/II studies, with preliminary data from CTX131 expected by the end of 2024 [7] Future Plans - Management is exploring additional indications for next-generation candidates and has initiated two new clinical studies for CTX131 and CTX112 [8] - The company is studying its first two in-vivo candidates, CTX310 and CTX320, in separate phase I clinical studies [9] - Plans to expand the in-vivo pipeline with CTX340 and CTX450 are underway, with clinical studies expected to start in the second half of 2025 [10] Market Performance - Shares of CRISPR Therapeutics have declined by 19.5% year-to-date, compared to a 3.8% decline in the industry [3] - The company currently holds a Zacks Rank 2 (Buy) [11]

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 24.06%. A quarter ago, it was expected that this company would post a loss of $1.37 per share when it actually produced a loss of $1.49, delivering a surprise of -8.76%.Over the last four quarters, the company has s ...

Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the North American market [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8%, primarily due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered three new international markets, contributing to a 20% increase in global sales [4]. - A new distribution center was opened in Europe to support the growing demand in the region [1]. - Strategic partnerships were formed with local retailers to enhance market penetration [2]. Product Development - Launched two new product lines, which accounted for 25% of total revenue in the last quarter [3]. - R&D investment increased by 10% to accelerate innovation and product differentiation [4]. - Customer feedback on the new products has been overwhelmingly positive, with a 90% satisfaction rate [1]. Operational Efficiency - Implemented new supply chain management software, reducing logistics costs by 5% [2]. - Streamlined manufacturing processes, resulting in a 7% increase in production output [3]. - Employee training programs were expanded, leading to a 15% improvement in operational efficiency [4]. Customer Engagement - Customer retention rate improved to 85%, up from 80% in the previous year [1]. - Launched a new loyalty program, which has already attracted 100,000 members [2]. - Enhanced customer service through the introduction of a 24/7 support hotline [3]. Financial Health - Total assets grew by 10%, reflecting the company's strong financial position [4]. - Debt-to-equity ratio decreased to 0.5, indicating improved financial stability [1]. - Cash flow from operations increased by 12%, providing more liquidity for future investments [2]. Strategic Initiatives - Announced a new sustainability initiative aimed at reducing carbon emissions by 20% over the next five years [3]. - Acquired a smaller competitor to expand market share and diversify product offerings [4]. - Board of Directors approved a new five-year strategic plan focusing on digital transformation and global expansion [1].

Regulatory Approvals and Clinical Trials - CASGEVY™ has received regulatory approvals for treating patients aged 12 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada, and is also approved in the U.S., Great Britain, EU, KSA, and Bahrain[3] - As of mid-October, 45 authorized treatment centers (ATCs) have been activated globally for CASGEVY, with approximately 40 patients having undergone cell collection across all regions[3] - Vertex has entered into a reimbursement agreement with NHS England for eligible TDT patients to access CASGEVY, and discussions are ongoing for SCD patients[4] - Enrollment has been completed in two global Phase 3 studies of CASGEVY in children aged 5 to 11 with SCD or TDT, with trials ongoing[4] - CTX112™ is currently in a Phase 1 clinical trial for relapsed or refractory CD19-positive B-cell malignancies, showing an overall response rate of 67% and a complete response rate of 44% in preliminary data from nine patients[5] - CTX310™ and CTX320™ are in ongoing Phase 1 clinical trials targeting ANGPTL3 and LPA, respectively, with updates expected in 2025[6] - CTX131 is a next-generation allogeneic CAR T product candidate targeting CD70, currently in clinical trials for relapsed or refractory solid tumors and hematologic malignancies[12] - CTX211 is an investigational therapy for type 1 diabetes, currently in a Phase 1 clinical trial, designed to enable insulin production in response to glucose[14] Financial Performance - The company reported a cash position of approximately $1.9 billion as of September 30, 2024, an increase from $1.7 billion as of December 31, 2023, primarily due to a $280 million direct offering and a $200 million milestone payment from Vertex Pharmaceuticals[8] - R&D expenses for Q3 2024 were $82.2 million, down from $90.7 million in Q3 2023, reflecting reduced external research and manufacturing costs[8] - The net loss for Q3 2024 was $85.9 million, an improvement from a net loss of $112.2 million in Q3 2023[8] - Total revenue for the nine months ended September 30, 2024, was $1,623,000, compared to $170,000 for the same period in 2023[19] - Research and development expenses for the nine months ended September 30, 2024, were $238,498,000, down from $292,188,000 in 2023[19] - The net loss for the nine months ended September 30, 2024, was $328,941,000, compared to $242,957,000 for the same period in 2023[19] - Cash and cash equivalents as of September 30, 2024, were $225,670,000, down from $389,477,000 as of December 31, 2023[20] - Total assets as of September 30, 2024, were $2,256,130,000, compared to $2,229,571,000 as of December 31, 2023[20] - Total shareholders' equity increased to $1,939,658,000 as of September 30, 2024, from $1,882,803,000 as of December 31, 2023[20] Product Development and Innovations - CRISPR Therapeutics has a proprietary lipid nanoparticle platform for delivering CRISPR/Cas9, with ongoing clinical trials for CTX310 and CTX320 targeting cardiovascular disease[13] - CRISPR Therapeutics celebrated the approval of CASGEVY (exa-cel) in late 2023 for treating sickle cell disease and transfusion-dependent beta thalassemia[15] - The company plans to present updates on its clinical trials and product candidates at the American Society of Hematology (ASH) 2024 Annual Meeting[2]

-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had cells collected across all regions as of mid-October- -Two clinical trials are ongoing for next generation CAR T product candidate, CTX112™ targeting CD19, in B-cell malignancies and systemic lupus erythematosus- -Two cl ...

It won't be able to be profitable without hitting its targets for both of these figures.Biotechs like CRISPR Therapeutics (CRSP 9.42%) can be tricky to invest in, as it isn't always obvious whether management's plans are working or not. Simply focusing on a big-picture figure like revenue often misses key points about what the company has done and where it's going.On that note, CRISPR's Q3 earnings will be reported sometime between Nov. 4 and Nov. 8 at the latest. When those results come out, investors shou ...

Core Viewpoint - CRISPR Therapeutics is expected to exceed expectations in its upcoming third-quarter 2024 results, despite a previous earnings miss of 8.76% in the last quarter [1][8]. Group 1: Upcoming Results - The Zacks Consensus Estimate for CRISPR's sales is $6.4 million, while the earnings estimate indicates a loss of $1.33 per share [1]. - The company's revenue is currently bolstered by grants and collaboration revenues from its partnership with Vertex Pharmaceuticals [2]. Group 2: Product Developments - CRISPR's gene therapy, Casgevy, has been approved for sickle cell disease and transfusion-dependent beta-thalassemia in the U.S. and Europe, with sales expected to start in the third quarter [3][4]. - The estimated share of gene therapy sales for CRISPR is projected at $5 million [4]. Group 3: Pipeline and Clinical Studies - CRISPR is developing next-generation CAR-T therapies, specifically CTX112 and CTX131, which are currently in phase I/II studies [5]. - New clinical studies have been initiated for CTX131 in hematological malignancies and CTX112 in systemic lupus erythematosus, with plans to explore additional autoimmune indications [6]. - The company is also studying in-vivo candidates CTX310 and CTX320 in separate phase I clinical studies [7]. Group 4: Earnings Performance - CRISPR has beaten earnings estimates in three of the last four quarters, with an average surprise of 101.83% [8]. - The company currently holds a Zacks Rank of 2 (Buy) and has an Earnings ESP of +100.00%, indicating a strong potential for an earnings beat [10][11].

Group 1 - CRISPR Therapeutics is a market leader in transformative therapies utilizing CRISPR/Cas9 biotechnology, with a significant partnership with Vertex Pharmaceuticals that has lasted for 9 years [1] - The FDA approved Casgevy in December 2023, followed by EMA approval in February 2024, indicating strong regulatory support for the product [1] Group 2 - The article emphasizes the importance of patient investing and the accumulation of high-quality assets, suggesting a balanced approach that includes both steady investments and high-risk opportunities [1]

This company might be worth far more than many realize.If I had to buy one share of any biotech with no price restriction, I'd naturally gravitate toward the most successful companies in the industry. However, the exercise becomes more complicated if you stipulate a limit of $50 per share; most of the prominent biotech stocks are trading well above that amount.Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that strong. Still, at least one ...